Table 1 Relations of positive rates by the three CTC detection techniques with clinicopathological variables and other molecular markers in blood

From: Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT–PCR in patients with metastatic breast cancer

  All patients CellSearch CTC test AdnaTest RT–PCR for CK-19 RT–PCR for mammaglobin RT–PCR CK-19 and/or mammaglobin
Characteristic N % N % P N % P N % P N % P N % P
ER                  
 Positive 51 71 21 81 0.20 15 94 0.02 15 75 0.63 29 74 0.47 33 73 0.55
 Negative 21 29 5 19   1 6   5 25   10 26   12 27  
PR                  
 Positive 37 53 13 52 0.84 9 60 0.53 9 47 0.57 21 57 0.49 23 53 0.89
 Negative 33 47 12 48   6 40   10 53   16 43   20 47  
HER2                  
 Positive 25 33 7 26 0.36 3 19 0.17 4 20 0.14 13 32 0.74 14 30 0.40
 Negative 50 67 20 74   13 81   16 80   28 68   33 70  
P53                  
 Positive 18 37 6 35 0.89 3 25 0.39 8 53 0.11 10 36 0.86 13 39 0.58
 Negative 31 63 11 65   9 75   7 47   18 64   20 61  
Disease status                  
 Progressive 46 63 22 81 0.02 12 75 0.22 15 75 0.19 25 64 0.84 30 67 0.41
 Non-progressive 27 37 5 19   4 25   5 25   14 36   15 33  
CA15.3 levels a
 High (109 U/ml) 34 51 22 85 <0.001 14 87 0.001 15 823 0.001 20 54 0.55 24 56 0.27
 Low (<109 U/ml) 33 49 4 15   2 13   3 17   17 46   19 44  
  1. Abbreviations: CTC=circulating tumour cell; ER=oestrogen receptor; PR=progesterone receptor; RT–PCR=reverse transcription–PCR.
  2. Statistically relevant relations are presented in bold.
  3. a Serum CA15.3 levels were dichotomised according to the median level in the breast cancer population.